Fabry disease is a rare genetic condition where the body can’t produce enough of a specific enzyme needed to break down fatty substances inside cells. Without this enzyme, a type of fat called globotriaosylceramide (Gb3) builds up in the tiny recycling centers of cells throughout the body, gradually damaging the kidneys, heart, brain, and nervous system. It affects an estimated 1 in 3,000 to 4,500 people, though many cases remain undiagnosed.
What Happens Inside the Body
Every cell contains structures called lysosomes that act like waste-processing plants, breaking down materials the cell no longer needs. In Fabry disease, a mutation in the GLA gene means the enzyme responsible for breaking down Gb3 is either missing or barely functional. The fat accumulates in lysosomes over months and years, swelling them and disrupting the cell’s normal operations. This isn’t limited to one organ. The buildup occurs in blood vessel walls, kidney cells, heart tissue, nerve fibers, and skin, which is why Fabry disease affects so many systems at once.
One of the cell types hit hardest is the podocyte, a specialized kidney cell that forms part of the blood filtration barrier. As Gb3 piles up in podocytes, they lose function and detach, gradually degrading kidney performance. Research has confirmed that the pathway disruptions aren’t unique to one cell type. Endothelial cells lining blood vessels and epithelial cells throughout the body show the same fundamental disturbances, pointing to a bodywide process rather than isolated organ damage.
Classic vs. Late-Onset Forms
Fabry disease exists on a spectrum, with two broadly recognized forms that differ in severity and timing.
The classic form is caused by severe genetic defects (large deletions, stop-codon mutations, or damaging missense mutations) that leave enzyme activity below 5% of normal in males. Symptoms begin in childhood and include neuropathic pain, skin lesions, gastrointestinal problems, and a characteristic change in the cornea. Without treatment, progressive kidney failure, heart disease, and brain lesions develop before middle age.
The late-onset form involves milder mutations that leave some residual enzyme activity (above 5%). People with this form often remain largely symptom-free until their 30s or later, when heart thickening (cardiomyopathy) typically becomes the first and sometimes only sign. Kidney and neurological problems can follow, but the overall course is slower. Late-onset Fabry disease is actually more common than the classic form, which contributes to its frequent misdiagnosis or delayed detection.
How Fabry Disease Is Inherited
The GLA gene sits on the X chromosome, which means the inheritance pattern differs between males and females. Males have one X chromosome, so a single mutated copy of the gene is enough to cause disease. Females have two X chromosomes, and in each cell, one is randomly switched off through a process called X-chromosome inactivation. If the chromosome carrying the healthy gene happens to be silenced in many cells, a woman can develop symptoms just as severe as a man’s. If the mutated copy is predominantly silenced, she may have a mild course or remain asymptomatic for decades.
This randomness means two women in the same family carrying the identical mutation can have dramatically different experiences. A father with Fabry disease will pass the mutation to all of his daughters and none of his sons. A mother who carries the mutation has a 50% chance of passing it to each child regardless of sex.
Early Symptoms in Childhood and Adolescence
In the classic form, the earliest signs usually appear in boys during childhood or early adolescence. The most recognizable is acroparesthesia: episodes of burning, tingling pain in the hands and feet that can be triggered by heat, exercise, fever, or stress. These pain crises can be debilitating and are often misattributed to growing pains or other conditions.
Sweating abnormalities are another early clue. Some children sweat far less than normal (hypohidrosis) or stop sweating entirely (anhidrosis), making them dangerously heat-intolerant. Others sweat excessively. Small dark-red skin lesions called angiokeratomas may appear around the belly button, groin, or thighs, sometimes as early as birth. Reduced tear production and gastrointestinal symptoms like cramping, bloating, and diarrhea round out the childhood picture. Because none of these symptoms are unique to Fabry disease on their own, the average time from first symptom to diagnosis can stretch for years.
Major Organ Damage Over Time
Left untreated, Gb3 accumulation takes a mounting toll on three organ systems in particular.
Kidneys
Kidney function declines steadily. In one large study of untreated patients, men lost kidney filtration capacity at an average rate of about 3 mL/min per year, while women lost about 1 mL/min per year. Proteinuria (excess protein in the urine) and high blood pressure both accelerate this decline. Many men with classic Fabry disease reach end-stage kidney failure by their 30s or 40s without intervention.
Heart
Cardiac events are the most common serious complication. In the same study, 49% of males and 35% of females experienced cardiac events, primarily arrhythmias, before starting treatment. The heart muscle thickens progressively, reducing its ability to pump and relax efficiently.
Brain
Strokes and transient ischemic attacks (mini-strokes) occurred in 11% and 6% of males, and 8% and 4% of females, respectively. These cerebrovascular events can happen at surprisingly young ages, sometimes in the 20s or 30s, and are occasionally the first recognized sign that leads to a Fabry diagnosis.
Life Expectancy
Data from the Fabry Registry found that life expectancy for men with Fabry disease was 58.2 years, compared to 74.7 years in the general U.S. population, a gap of about 16 years. For women, life expectancy was 75.4 years versus 80.0 years, a smaller but still meaningful reduction. The leading causes of death were serious cardiac and kidney dysfunction. Late diagnosis was identified as a likely contributor to many of these early deaths, underscoring the importance of catching the disease before irreversible organ damage sets in.
How Fabry Disease Is Diagnosed
The diagnostic path differs for males and females. In males, the first step is measuring enzyme activity through a blood test. Activity below 1% of normal is strongly suggestive of classic Fabry disease. Males with borderline activity (5 to 10%) need genetic testing to confirm the diagnosis. The enzyme test alone is not sufficient for either sex, because genetic confirmation is required in all cases.
For females, the enzyme test is even less reliable. Because of X-chromosome inactivation, a woman carrying the mutation can show enzyme activity anywhere from severely low to completely normal. Genetic testing is the only definitive way to diagnose or rule out Fabry disease in women. Newborn screening programs have begun identifying the condition earlier in some regions, but most diagnoses still happen after symptoms prompt clinical investigation.
Treatment Options
Two main treatment approaches are currently available, both aimed at reducing Gb3 accumulation rather than curing the underlying genetic defect.
Enzyme replacement therapy (ERT) has been the standard treatment for over 20 years. It involves intravenous infusions of a manufactured version of the missing enzyme, given every two weeks. Two forms exist: agalsidase alfa and agalsidase beta. ERT can slow organ damage, reduce pain episodes, and stabilize kidney function, though its effectiveness depends heavily on how early treatment begins. Once significant scarring has occurred in the kidneys or heart, ERT is less able to reverse it.
An oral alternative called migalastat (brand name Galafold) was approved by the FDA in 2018. Rather than replacing the enzyme, it works as a chaperone: it binds to the patient’s own misfolded enzyme and helps it fold correctly so it can function. It’s taken as a capsule every other day. The catch is that migalastat only works for patients whose specific mutation produces an enzyme that responds to chaperoning. Before starting treatment, the mutation must be checked against an amenability table. The drug is approved for patients 12 and older with adequate kidney function.
Ongoing Monitoring
Because Fabry disease affects multiple organs simultaneously, management requires regular check-ins across specialties. Patients on treatment typically undergo comprehensive assessments every six months, including heart imaging (echocardiograms, cardiac MRI), kidney function tests (protein in urine, filtration rate), blood pressure checks, pain evaluations, and biomarker tracking. The goal at each visit is to confirm that symptoms are stable or improving and that quality of life is maintained.
People who carry the genetic mutation but haven’t yet developed symptoms are also monitored, though less frequently. For male carriers with the classic form, annual follow-up is standard. For females and those with later-onset mutations, the schedule may be every two to three years initially, tightening to annual visits as they approach the age when organ involvement typically begins. This proactive surveillance is designed to catch the first signs of organ damage early enough to intervene before it becomes irreversible.